Introduction 49
Chaperonin 10 (Cpn10) is a member of the stress or heat shock family of proteins. This 50 group of proteins is among the most highly conserved in nature, with respect to both 51 structure and function. Human Cpn10 has 100% homology with bovine, porcine and 52 rabbit Cpn10 while rat Cpn10 differs from human by one amino acid [1] . Localized in 53 various intracellular compartments, heat shock proteins (HSPs) have a well-defined role in 54 protein assembly, translocation and degradation. Cpn60 together with its co-chaperone 55 Cpn10, reside primarily within mitochondria where they fulfil an essential role in 56 mitochondrial protein folding [2] . Stress proteins are up-regulated in response to hypoxia, 57 hypoglycaemia, ionising radiation and heat-shock [3, 4] and released from cells through as 58 yet undefined mechanisms. Once in the extracellular environment, a number of stress 59
proteins have demonstrated autocrine, paracrine and endocrine immunological activity [5] . 60
Cpn10 has demonstrated anti-inflammatory and immunoregulatory activity and has been 61 proposed as a member of the resolution-associated molecular patterns (RAMPs) family of 62 molecules [6] . As a RAMP, Cpn10 is hypothesised to regulate the acute immune response 63 with therapeutic potential to restore homeostasis in a dysregulated setting such as chronic 64 inflammation and autoimmune disease. 65 66 Cpn10 members are dome-shaped, heptameric rings comprised of identical 10 kDa 67 subunits [7 8 ]. The test material described herein is Cpn10 produced in bacteria as a 68 recombinant protein.
An N-terminus comparison of native human Cpn10 with 69 recombinant Cpn10 reveals the substitution of two hydrogen (H) groups for a methyl (CH 3 ) 70
and an amino (NH 3 + ) group in recombinant Cpn10 (Ala-Cpn10). 71 A c c e p t e d M a n u s c r i p t 6 performed in the early stages of bioprocess development, and following subsequent 124 changes to the bioprocess. Apart from meeting specifications for process-related 125 impurities, an important facet of bioprocess optimisation is minimising levels of product 126 variant. 127
128
In compliance with regulatory requirements and in order to facilitate the safe and effective 129 testing of Cpn10 administration in patients with autoimmune disease, it was essential that a 130 rigorous purification methodology be devised to remove process-related impurities from 131 
Cloning and expression of human Cpn10 in E. coli 146
Initial cloning and expression of Cpn10 was as described in Somodevilla-Torres et al. 147 (2003) [18] . Ala-Cpn10 pPL550, a heat-inducible expression plasmid encoding human 148
Cpn10 with an additional N-terminal alanine was transformed into XL1-Blue and Cpn10 In brief, 100 L fed batch-fermentations for Cpn10 were carried out as follows. An 177 inoculum culture, derived from a vial of the WCB, was grown in Vegetable Peptone Broth 178 supplemented with kanamycin. The inoculum was used to seed a 150 L fermenter 179 containing 75 L chemically defined batch media (without antibiotic selection) and 180 following overnight batch growth, the glucose based nutrient feed was supplied on demand. 181
The cultivation temperature was maintained at 37 ± 2 °C throughout, pH maintained at 7 ± 182 0.3 by the addition of an ammonia solution and dissolved oxygen was maintained at >30%. collected. SDS-PAGE analysis showed the SP-BB pool to be >95% pure (data not shown). 217
218

BR067 Cell Line 219
The filtered lysate was loaded over ~110 min onto a SP-BB cation exchange column (BPG 220 300/500 with 18 L of SP-BB Sepharose resin, GE Biosciences) pre-equilibrated with 221
Buffer A, at 75 cm h -1 linear flow-rate and a loading rate of up to 31 g Cpn10 L -1 of resin. 222
After washing with Buffer A, the captured Cpn10 was eluted with Buffer A containing 150 223 mM NaCl and a single fraction of 9-16 L was collected. SDS-PAGE analysis showed the 224 SP-BB pool to be >95% pure. The pooled SP-HP fractions were diluted with 50 mM Tris-HCl pH 7.6 to 5 mg/mL. Prior 251 to dilution with 50 mM Tris-HCl pH 7.6, NaCl was dissolved in the buffer to achieve Na by injecting 100 μL onto the column and separated by isocratic elution at a flow rate of 0.5 295 mL/min using 50 mM Sodium Phosphate pH 7.0 + 150 mM NaCl as the elution buffer. 296
The apparent molecular weight of eluting species was estimated by comparison of peak 297 retention times with globular protein standards of a known molecular weight. 298
299
Glutaraldehyde cross-linking of Cpn10 300
An amount of 580 µg of human recombinant Cpn10 in PBS (pH 7.4) was incubated with 301 0.01 % (w/w) glutaraldehyde (APS) in a total volume of 300 µL at 25 °C for 30 min. 302
Reactions were quenched by the addition of 15 µL of 2 M Tris-HCl pH 8.0. An aliquot of 303 the reaction mixture was analysed by size exclusion chromatography to separate the 304 different oligomeric species and the peak eluting at the same retention time as the nonM a n u s c r i p t 13 cross-linked Cpn10 oligomer was collected in two 0.5 mL fractions and analysed by SDS-306 PAGE with silver staining. 307 308
Stability testing of purified and formulated Cpn10 309
Cpn10 batches 1, 2 and 3 (Table I) 
Results and Discussion 368
Production strain development 369
Bioprocess development from the initial stages of protein expression through to generation 370 of the final production strain incorporates a number of optimisation steps. The strain used 371 in early, small-scale bioprocess development may not be the optimal strain for large-scale 372 production, for reasons that include suitability of media formulation, promoter system, 373 levels of product variants and choice of selectable marker. For example, codon 374 optimisation is generally required to maximise expression and minimise the level of 375 product variant(s) due to mistranslation at rare codons. 376
377
In the early stages of bioprocess development Cpn10 production was performed in XL1-378
Blue cells utilising a heat-inducible promoter system (pPL550:cpn10). The XL1-Blue 379 expression system has been described previously in the literature [18 20 ] however, as will 380 be shown, was found to be inadequate for large-scale production. Bioprocess optimisation 381 ultimately resulted in the production of Cpn10 for Phase IIa clinical trials in strain BR067 382 from an IPTG inducible tac promoter-based expression construct. Figure 1 
development. Cpn10 is a heptamer of molecular weight (M r ) 70 kDa, with the monomeric 385 form visualised at M r 10 kDa by SDS-PAGE. Cpn10 yield (g L -1 ) in the optimised BR067 386 strain fermentate increased around 8-9 fold and improved product purity from ~88% to 387 97% compared to product made in the XL1-Blue strain (Table I) . Importantly, total 388 product variants, as a percentage of purified Cpn10, were reduced from 12.1% in the XL1-389
Blue system to 3.2% in the final BR067 production strain (Table IB) . 390
391
Although the XL1-Blue strain allowed production of sufficient quantities of Cpn10 for 392 early stage product development, there were a number of drawbacks. The inadequacies 393 included the requirement for complex media, use of β-lactam-based antibiotics which can 394 potentially cause allergic reactions, the difficult to control heat shock inducible promoter at 395 large fermentation volumes, inability to achieve high cell densities and generation of 396 unacceptably high levels of mistranslation variants. The removal of product variants was 397 first attempted by total codon optimisation of the human Cpn10 cDNA for production in E. on residue K40 (Fig. 1C) . For this reason, partial codon optimisation first targeted the rare 406 glycine codon encoding residue G39 in the human Cpn10 cDNA. Figure 1A shows that 407 equivalent expression levels were obtained with the wild type (wt) Cpn10 cDNA and the 408 G39 codon optimised (G39-opt) cDNA when produced from the XL1-Blue strain, butA c c e p t e d M a n u s c r i p t more importantly, the Cpn10-G39E variant peak visible by RP-HPLC was significantly or 410 completely removed (data not shown). 411
412
Given the inability of XL1-Blue to achieve high cell densities (Table IA) , expression of the 413 wt and G-opt cDNAs from the heat-inducible promoter system (pPL550:cpn10) was next 414 attempted in BR067 cells. Again equivalent expression levels were obtained with the wt 415 Cpn10 cDNA and the G39 codon optimised (G39-opt) cDNA when produced from BR067 416 cells (Fig. 1A) . However as expected, BR067 ferments typically reached a cell density of 417 OD 600nm ~110 (data not shown) compared to XL1-Blue ferments which only reached a cell 418 density of OD 600nm ~25 (Table IA) termination sequence in the BR067 cell line (Fig. 1B and data not shown) . All subsequent 433 work was completed in this production system. 434
A c c e p t e d M a n u s c r i p t
18
The establishment of an optimal expression system and continual efforts to improve the 436 RP-HPLC method, for detection and quantitation of Cpn10 production variants, uncovered 437 yet additional inadequacies in the wt and partially codon optimised Cpn10 cDNA. A 438 combination of removal of Cpn10-G39E variant and optimisation of the RP-HPLC 439 gradient, revealed the presence of small amounts (~1%) of new production variant Cpn10-440 G39D (data not shown). A decision was made to attempt to optimise all rare glycine 441 codons within Cpn10 to prevent the unforeseen appearance of further trace amounts of 442 glycine variants as the program progressed. Figure 1B shows that equivalent expression 443 levels were obtained with the wt Cpn10 cDNA, the G39 codon optimised (G39-opt) cDNA 444 and when all rare glycine codons were optimised (G-opt) in the Cpn10 cDNA. RP-HPLC 445 analysis of Cpn10 from the all glycine codon optimised construct, revealed that while the 446 major G39E + acetylated K40 peak had been minimised, two new additional peaks were 447 present (Fig. 1C, G-opt) . 
Confirmation of heptameric structure 478
Cpn10 is a heptamer, made up of seven identical monomers. SDS-PAGE analysis of 479 Cpn10 derived from BR067 production strain is shown in Figure 2A that only intra-oligomer cross-linked species were isolated. SDS-PAGE analysis of this 489 material revealed seven discrete protein bands, representing Cpn10 monomer and cross-490 linked dimer, trimer etc. through to heptamer, indicating that Cpn10 adopts a heptameric 491 structure that is characteristic of all Cpn10 members (Fig. 2B) . The apparent molecular 492 weight of heptameric Cpn10 was determined to be 94 ± 3 kDa (Fig. 2C) . The expected 493 theoretical molecular weight of heptameric Cpn10 was estimated at 76kDa using the 494 ExPasy Protein Parameter analysis tool (SIB; Swiss Institute of Bioinformatics). The slight 495 discrepancy in apparent molecular weight could be attributed to the expanded packing of 496 the subunits within the Cpn10 heptamer resulting in an increased Stokes radius. 497
498
Activity and stability of purified, recombinant Cpn10 499
The biological activity of Cpn10 (over time) was investigated as a molecular co-chaperone 500 in protein folding, and was used as an indicator for structural integrity. Cpn10 (>99% pure) 501 expressed in E. coli was formulated in 50 mM Tris-HCl (pH 7.6) and 150 mM NaCl. 502
When stored at ~75 mg mL -1 and 2-8 o C for at least 3 years, Cpn10 retained full activity as 503 a co-chaperone in the process of E. coli GroEL-mediated rhodanese refolding (Fig. 2D) . 504
The bioassay revealed that small differences in Cpn10 activity can be detected by varying 505 the amount of Cpn10, illustrating its usefulness for ensuring the integrity of Cpn10 506 production batches. In agreement with the retention of full biological activity after 3 years 507 stored at 2-8 o C, no significant changes to the product variant profile were observed by RP-508 HPLC and no changes were observed to the heptameric structure by SEC (data not shown). 509
Cpn10 is therefore a very stable protein, which is probably not unexpected given that it is a 510 stress-inducible protein and fulfils an essential role in the maintenance of cellular 511 homeostasis. 512 M a n u s c r i p t
513
Methionine oxidation can have significant effects on the activity of a protein; for example, 514 oxidation of the exposed, N-terminal-methionine of α-polypeptide in the light-harvesting 515 complex from Rhodospirillum rubrum affects its ability to form the B820 subunit with β-516 polypeptide and bacteriochlorophyll a [23]. Cpn10 contains a single Met residue at 517 position 33 of the mobile loop (i.e. 32-Ile-Met-Leu-34), which is crucial for its efficient 518 interaction with Cpn60. Therefore, potential oxidation of this Met residue was investigated 519 by mass spectrometry. Tandem mass spectra of Cpn10 indicated the Met residue is readily 520 oxidised by hypochlorite (data not shown), however only 0.5% of the purified Cpn10 521 material was observed to be oxidized at the end of production (Table IB) . More 522 importantly, storage at ~75 mg mL -1 under nitrogen for 3 years at 2-8 o C resulted in <1.5 % 523 product oxidation, indicating that oxidation will not be a concern for biological activity. 524
525
Mass spectrometry 526
The mass of purified Cpn10, determined by mass spectrometry was 10,872.2 ± 1 Da (data 527 not shown), in agreement with the theoretical mass of 10,871.5 Da. To confirm the 528 primary sequence of Cpn10, a tryptic peptide map was developed and the 14 resulting 529 peptides were identified by mass spectrometry (Fig. 3) . The mass spectrometry-based 530 identity of the peptides in peaks 1, 10, 13 and 14, was corroborated by their strong 531 absorbance at A 280nm as peptides containing tyrosine residues (data not shown). Mass 532 spectrometry was an invaluable tool for monitoring product integrity during process 533 development and for tracking the level of product variants. 534
535
Purified recombinant Cpn10 lacks proinflammatory E. coli contaminants 536
The observed effects of recombinant heat shock protein preparations on the immune 537 system have been quite controversial owing to the potential presence of pro-inflammatoryA c c e p t e d M a n u s c r i p t
22
E. coli components that may alone be responsible for activity [24] . To illustrate that 539 recombinant Cpn10 preparations lacked major E. coli pro-inflammatory contaminants, 540
highly sensitive HEK reporter cell lines transfected with either TLR2, TLR3, 541 TLR4/MD2/CD14 or TLR9 were used. Figure 4 shows that when TLR-transfected HEK 542 cells were challenged with aliquots of Cpn10 from three separate GMP batches of BR067, 543 readouts were below the level of detection for the appropriate ligand, indicating a robust 544 downstream process that yields Cpn10 preparations that are essentially free of bacterially-545 derived contaminants. 546
547
GMP production of Cpn10 548
Human Cpn10 was produced in the E. coli BR067 production strain in 100 L fed-batch 549 fermentations performed under cGMP at Hospira, Adelaide, Australia. Cpn10 protein was 550 completely soluble and purified from the cellular lysate after disruption and clarification. 551
Compared to XL1-Blue at the same fermentation scale, use of the BR067 strain resulted in 552 an ~5 fold increase in cell density and an ~9-fold increase in expression levels which 553 ultimately resulted in a near 6-fold increase in final product. 554 555 Cpn10 was purified by a downstream process incorporating three sequential IEX 556 chromatography steps; SP-BB, Q-FF and SP-HP chromatography (Table IA) . Throughout 557 the downstream process, chromatographic fractions were analysed by RP-HPLC for purity 558 and yield of Cpn10 (Table IA) mass spectrometry indicated that it was identical to material retained on the SP-BB resin. 569
An attempt to dissociate Cpn10 from an unknown bound entity using urea or organic 570 alcohols improved binding to >90%, however led to the formation of an apparent Cpn10 571 heptamer dimer (<20% of total Cpn10) (data not shown). A decision was made to accept 572 the lower Cpn10 recovery on SP-BB to achieve the maximum purity. 573
574
Operation of Q-FF IEX chromatography at pH 8.0 ensured that the Cpn10 was contained 575 in the flow-through, whilst residual host cell proteins, DNA and endotoxin bound to the 576 column. The SP-HP final polishing step resulted in the production of clinical grade Cpn10, 577 with a purity >99% by SDS-PAGE. Table IB shows the product variant profile for three  578 cGMP Cpn10 batches and an average product variant level of 3.3%. Table IB additionally  579 shows numerous Cpn10 characterisation tests which ensure suitability for human 580 administration. Endotoxin (<0.6 EU mg -1 ), based on dosage levels, is well below the 581 required limit of 5 EU kg -1 body weight per hr for an intravenous application of a 582 therapeutic protein [26] . 583
584
GMP formulation of Cpn10 585
Cpn10 bulk drug substance (BDS) was manufactured by Hospira, a GMP facility in 586
Adelaide, South Australia. Hospira has produced Cpn10 at a manufacturing scale (100L) 587 to supply material for preclinical and clinical studies, preparation of a reference lot, and 588 stability studies. Cpn10 produced from the cell line XL-1Blue was manufactured for phase A bioprocess for the production of ~115 g of clinical grade Cpn10 (representing an overall 607 recovery of 26%) from a 100 L E. coli fermentation was developed incorporating cation 608 and anion exchange chromatography purification. Cpn10 was characterised with respect to 609 purity by SDS-PAGE (> 99%), identification of product variants (3.2%), in vitro biological 610 activity and stability. Key improvements to process productivity were achieved through 611 changing the host production cell line, the choice of promoter and termination sequences 612 and through partial codon optimisation. These changes resulted in elevated final cell 613 density in the bioreactor, higher specific Cpn10 productivity and reduced the proportion of 614 product variants, which was critical for the production of clinical-grade protein. 615 Biochemical stability testing revealed no loss in chaperone activity and no significant Upstream data for production of Cpn10 in host strains XL1-Blue and BR067, and 708 downstream processing unit operations for purification of Cpn10 from BR067 production 709 strain cell lysate, including Cpn10 purity and recovery for each unit operation. 
